생리 활성 드레싱 시장 : 제품별, 특성 유형별, 용도별, 최종 사용자별, 지역별 - 예측(-2029년)

The global bioactive dressings market is projected to reach USD 5.8 billion by 2029 from USD 3.5 billion in 2024, at a CAGR of 10.5% during the forecast period. The rising incidence of chronic wounds and the increasing elderly population are the major drivers boosting the demand for bioactive dressings. Technology advancements in wound dressings and increased awareness of the benefits like faster healing and patient comfort, are driving market growth, with further expansion anticipated due to ongoing innovation.

"Bioactive dressings segment accounted for the highest market share in the bioactive dressings market, by product type, during the forecast period."

Based on product type, the bioactive dressings market is divided into bioactive dressings and skin substitutes. In 2023, the bioactive dressings segment led the market. The growth of this segment is primarily driven by the increasing prevalence of chronic, surgical, and traumatic wounds; a rising number of burn injuries; technological advancements in bioactive dressings; and increased spending on the treatment of chronic and surgical wounds

"Chronic wound segment accounted for the highest market share in the bioactive dressings market, by application, during the forecast period."

Based on application, the bioactive dressings market is divided into acute wounds and chronic wounds. In 2023, the chronic wounds segment held the largest market share. The majority share of this segment is attributed to the increasing elderly population and the rising incidence of chronic wounds, including diabetic foot ulcers, pressure ulcers, arterial ulcers and venous leg ulcers, among others.

"Home Care Settings accounted for the highest CAGR during the forecast period."

Based on end user, the bioactive dressings market is segmented into hospitals and clinics, long-term care facilities, home care settings, and other end users. In 2023, hospitals and clinics held the largest market share. However, home care settings are projected to grow at the highest CAGR during the forecast period, mainly due to their cost-efficiency compared to hospitals, as well as the convenience and comfort they offer.

"The North America segment accounted for the highest market share in the bioactive dressings market, by region, during the forecast period."

Bioactive dressings market is divided into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), the Middle East & Africa (MEA) and GCC Countries. During the forecast period the North America is expected to witness a larger market share. The expansion of the bioactive dressings market in North America is fueled by the high prevalence of chronic wounds, advancements in bioactive dressing technologies, and increased healthcare spending.

Breakdown of supply-side primary interviews by company type, designation, and region:

• By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
• By Designation: C-level (30%), Director-level (20%), and Others (50%)
• By Region: North America (42%), Asia- Pacific (31%), Europe (20%), Latin America- (4%) and MEA-(2%), and GCC (1%).

Prominent companies include 3M (US), Smith+Nephew (UK), Cardinal Health (US), B. Braun SE (Germany), Molnlycke Health Care AB (Sweden), Convatec Inc. (UK), Paul Hartmann Ag (Germany), Coloplast Corp (Denmark), Integra LifeSciences Corporation (US), Organogenesis Inc.(US), Essity(Sweden), Covalon Technologies(Canada), Mimedx Group, Inc.(US), Sanara Medtech Inc.(US), Medline Industries, LP.(US), Hollister Incorporated(US), Lohmann & Rauscher (L&R) (Germany), DermaRite Industries, LLC (US), BioTissue (US), LifeNet Health (US), Advancis Medical(UK), Human BioSciences (US), AMERX Health Care (US), Gentell (US) and Axio Biosolutions Pvt Ltd (India).

Research Coverage

This research report categorizes the bioactive dressings market by product type, property type, application, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the bioactive dressings market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, services; key strategies; Contracts, partnerships, and agreements. New product launches, mergers and acquisitions, and recent developments associated with the bioactive dressings market. Competitive analysis of upcoming startups in the bioactive dressings market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall bioactive dressings market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the bioactive dressings market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the bioactive dressings market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the bioactive dressings market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bioactive dressings market
• Competitive Assessment: In-depth assessment of market ranking, growth strategies, and service offerings of leading players like 3M (US), Smith+Nephew (UK), Cardinal Health (US), B. Braun SE (Germany), Molnlycke Health Care AB (Sweden), Convatec Inc. (UK), Paul Hartmann Ag (Germany), Coloplast Corp (Denmark), Integra LifeSciences Corporation (US), Organogenesis Inc.(US), Covalon Technologies(Canada), and Mimedx Group, Inc.(US) among others in the bioactive dressings market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 BIOACTIVE DRESSINGS MARKET SEGMENTATION
  • 1.3.2 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.1.2 Approach 3: Presentations of companies and primary interviews
    • 2.2.1.3 Growth forecast
    • 2.2.1.4 CAGR projections
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.4 STUDY ASSUMPTIONS
  • 2.4.1 GROWTH RATE ASSUMPTIONS
  • 2.4.2 LIMITATIONS
• 2.5 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BIOACTIVE DRESSINGS MARKET OVERVIEW
• 4.2 BIOACTIVE DRESSINGS MARKET SHARE, BY PRODUCT, 2024 VS. 2029
• 4.3 BIOACTIVE DRESSINGS MARKET SHARE, BY TYPE, 2024 VS. 2029
• 4.4 SKIN SUBSTITUTES MARKET SHARE, BY TYPE, 2024 VS. 2029
• 4.5 BIOACTIVE DRESSINGS MARKET SHARE, BY PROPERTY TYPE, 2024 VS. 2029
• 4.6 BIOACTIVE DRESSINGS MARKET SHARE, BY APPLICATION, 2024 VS. 2029
• 4.7 BIOACTIVE DRESSINGS MARKET SHARE FOR CHRONIC WOUNDS, BY TYPE, 2024 VS. 2029
• 4.8 BIOACTIVE DRESSINGS MARKET SHARE FOR ACUTE WOUNDS, BY TYPE, 2024 VS. 2029
• 4.9 BIOACTIVE DRESSINGS MARKET SHARE, BY END USER, 2024 VS. 2029
• 4.10 BIOACTIVE DRESSINGS MARKET SHARE FOR HOSPITALS & CLINICS, BY TYPE, 2024 VS. 2029
• 4.11 BIOACTIVE DRESSINGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising prevalence of chronic wounds
    • 5.2.1.2 Growing geriatric population
    • 5.2.1.3 Increasing number of surgical procedures worldwide
    • 5.2.1.4 Increasing incidence of burn injuries
    • 5.2.1.5 Advancements in bioactive dressing technology
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High costs of bioactive dressing products
    • 5.2.2.2 Limited reimbursement policies
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth potential of emerging countries
    • 5.2.3.2 New product development
    • 5.2.3.3 Strategic collaboration between market players
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Difficult regulatory approval process
    • 5.2.4.2 Lack of awareness and education
• 5.3 PRICING ANALYSIS
  • 5.3.1 AVERAGE SELLING PRICE TREND OF BIOACTIVE DRESSINGS
  • 5.3.2 AVERAGE SELLING PRICE OF BIOACTIVE DRESSINGS, BY REGION
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 BIOACTIVE DRESSINGS MARKET: ROLE IN ECOSYSTEM
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 THREAT OF NEW ENTRANTS
  • 5.8.2 THREAT OF SUBSTITUTES
  • 5.8.3 BARGAINING POWER OF BUYERS
  • 5.8.4 BARGAINING POWER OF SUPPLIERS
  • 5.8.5 DEGREE OF COMPETITION
• 5.9 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.9.2 BUYING CRITERIA
• 5.10 REGULATORY ANALYSIS
  • 5.10.1 REGULATORY LANDSCAPE
    • 5.10.1.1 North America
      • 5.10.1.1.1 US
      • 5.10.1.1.2 Canada
    • 5.10.1.2 Europe
    • 5.10.1.3 Asia Pacific
      • 5.10.1.3.1 China
      • 5.10.1.3.2 Japan
      • 5.10.1.3.3 India
    • 5.10.1.4 Latin America
      • 5.10.1.4.1 Brazil
      • 5.10.1.4.2 Mexico
    • 5.10.1.5 Middle East
    • 5.10.1.6 Africa
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 TRADE ANALYSIS
  • 5.11.1 TRADE ANALYSIS FOR WADDING, GAUZE, AND BANDAGES
• 5.12 TECHNOLOGY ANALYSIS
  • 5.12.1 KEY TECHNOLOGIES
    • 5.12.1.1 Kollagen technology
  • 5.12.2 COMPLEMENTARY TECHNOLOGIES
    • 5.12.2.1 Bioactive microfiber gelling technology
  • 5.12.3 ADJACENT TECHNOLOGIES
    • 5.12.3.1 Kerecis intact fish skin technology
• 5.13 KEY CONFERENCES & EVENTS, 2024-2025
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 IMPACT OF AI ON BIOACTIVE DRESSINGS MARKET

6 BIOACTIVE DRESSINGS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 BIOACTIVE DRESSINGS
  • 6.2.1 COLLAGEN DRESSINGS
    • 6.2.1.1 Unique healing properties and biocompatibility to drive growth
  • 6.2.2 ALGINATE DRESSINGS
    • 6.2.2.1 Excellent absorption capacity to boost demand for alginate dressings
  • 6.2.3 CHITOSAN DRESSINGS
    • 6.2.3.1 Rising need for effective, natural wound healing options to support market growth
  • 6.2.4 HONEY DRESSINGS
    • 6.2.4.1 Effective and natural wound care management to fuel growth
  • 6.2.5 OTHER BIOACTIVE DRESSINGS
• 6.3 SKIN SUBSTITUTES
  • 6.3.1 HUMAN DONOR TISSUE-DERIVED PRODUCTS
    • 6.3.1.1 High efficacy of human donor tissue-derived products to support market demand
  • 6.3.2 ACELLULAR ANIMAL-DERIVED PRODUCTS
    • 6.3.2.1 Recognition of importance of ECM in wound treatment to boost development of acellular wound care biologics
  • 6.3.3 BIOSYNTHETIC PRODUCTS
    • 6.3.3.1 Increased bioburden of infected wounds to stimulate market growth

7 BIOACTIVE DRESSINGS MARKET, BY PROPERTY TYPE

• 7.1 INTRODUCTION
• 7.2 NON-ANTIMICROBIAL DRESSINGS
  • 7.2.1 COST-EFFECTIVENESS COMPARED TO ANTIMICROBIAL DRESSINGS TO BOOST MARKET
• 7.3 ANTIMICROBIAL DRESSINGS
  • 7.3.1 EFFECTIVENESS IN PREVENTING AND MANAGING INFECTIONS TO DRIVE GROWTH

8 BIOACTIVE DRESSINGS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 CHRONIC WOUNDS
  • 8.2.1 DIABETIC FOOT ULCERS
    • 8.2.1.1 Increasing prevalence of diabetes to drive growth
  • 8.2.2 PRESSURE ULCERS
    • 8.2.2.1 Growing geriatric population to drive demand for bioactive dressings
  • 8.2.3 VENOUS LEG ULCERS
    • 8.2.3.1 Rising prevalence of obesity to boost adoption
  • 8.2.4 OTHER CHRONIC WOUNDS
• 8.3 ACUTE WOUNDS
  • 8.3.1 SURGICAL WOUNDS
    • 8.3.1.1 Rising volume of surgical procedures to support market growth
  • 8.3.2 TRAUMATIC WOUNDS
    • 8.3.2.1 Increasing number of road accidents to drive growth
  • 8.3.3 BURNS
    • 8.3.3.1 High incidence of burn injuries to propel market growth

9 BIOACTIVE DRESSINGS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS & CLINICS
  • 9.2.1 INPATIENT SETTINGS
    • 9.2.1.1 Increasing hospital admissions due to HAIs to drive growth
  • 9.2.2 OUTPATIENT SETTINGS
    • 9.2.2.1 Rising costs of inpatient facilities to drive demand for outpatient care settings
• 9.3 HOME CARE SETTINGS
  • 9.3.1 LOW COSTS AND CONVENIENCE TO DRIVE GROWTH
• 9.4 LONG-TERM CARE FACILITIES
  • 9.4.1 GROWTH IN GERIATRIC & VULNERABLE POPULATIONS TO BOOST DEMAND FOR BETTER LONG-TERM CARE
• 9.5 OTHER END USERS

10 BIOACTIVE DRESSINGS MARKET, BY REGION

• 10.1 INTRODUCTIONS
• 10.2 NORTH AMERICA
  • 10.2.1 US
    • 10.2.1.1 Rising prevalence of chronic diseases to drive market
  • 10.2.2 CANADA
    • 10.2.2.1 Growing awareness about diabetes and its associated complications to fuel market
• 10.3 EUROPE
  • 10.3.1 GERMANY
    • 10.3.1.1 Rising focus on medical technology clusters to boost market
  • 10.3.2 UK
    • 10.3.2.1 Increasing prevalence of surgeries to aid growth
  • 10.3.3 FRANCE
    • 10.3.3.1 Surge in elderly population to propel market
  • 10.3.4 ITALY
    • 10.3.4.1 Improved life expectancy to support growth
  • 10.3.5 SPAIN
    • 10.3.5.1 Increasing median age to augment growth
  • 10.3.6 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 CHINA
    • 10.4.1.1 Growing incidence of diabetic foot ulceration to drive market
  • 10.4.2 JAPAN
    • 10.4.2.1 Expanding hospital infrastructure to fuel market
  • 10.4.3 INDIA
    • 10.4.3.1 Booming medical tourism in India to boost market
  • 10.4.4 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 BRAZIL
    • 10.5.1.1 Presence of large patient population to stimulate growth
  • 10.5.2 MEXICO
    • 10.5.2.1 Growing awareness about effective wound care approaches to support growth
  • 10.5.3 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 GROWING DEMAND FOR HEALTHCARE FACILITIES TO AID MARKET GROWTH
• 10.7 GCC COUNTRIES
  • 10.7.1 FAVORABLE HEALTHCARE INFRASTRUCTURE AND INITIATIVES TO BOOST MARKET

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOACTIVE DRESSINGS MARKET
• 11.3 REVENUE ANALYSIS
• 11.4 MARKET SHARE ANALYSIS
  • 11.4.1 RANKING OF KEY MARKET PLAYERS
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Product footprint
    • 11.5.5.3 Property footprint
    • 11.5.5.4 Application footprint
    • 11.5.5.5 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.7.1 FINANCIAL METRICS
  • 11.7.2 COMPANY VALUATION
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS
  • 11.9.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 SMITH+NEPHEW
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Expansions
      • 12.1.1.3.2 Other developments
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 ORGANOGENESIS INC.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product approvals
      • 12.1.2.3.2 Other developments
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 MIMEDX GROUP, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches and approvals
      • 12.1.3.3.2 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 3M
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Other developments
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 CARDINAL HEALTH
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 MnM view
      • 12.1.5.3.1 Key strengths
      • 12.1.5.3.2 Strategic choices
      • 12.1.5.3.3 Weaknesses and competitive threats
  • 12.1.6 B. BRAUN SE
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
  • 12.1.7 MOLNLYCKE AB
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
  • 12.1.8 CONVATEC INC.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product approvals
      • 12.1.8.3.2 Deals
  • 12.1.9 PAUL HARTMANN AG
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 COLOPLAST CORP.
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Deals
  • 12.1.11 INTEGRA LIFESCIENCES CORPORATION
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Deals
  • 12.1.12 ESSITY AKTIEBOLAG
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Product launches
      • 12.1.12.3.2 Deals
  • 12.1.13 COVALON TECHNOLOGIES LTD.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Other developments
  • 12.1.14 SANARA MEDTECH
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Product launches
      • 12.1.14.3.2 Deals
• 12.2 OTHER PLAYERS
  • 12.2.1 MEDLINE INDUSTRIES, INC.
  • 12.2.2 HOLLISTER INCORPORATED
  • 12.2.3 L&R GROUP
  • 12.2.4 DERMARITE INDUSTRIES, LLC
  • 12.2.5 BIOTISSUE
  • 12.2.6 LIFENET HEALTH
  • 12.2.7 ADVANCIS MEDICAL
  • 12.2.8 HUMAN BIOSCIENCES
  • 12.2.9 AMERX HEALTH CARE
  • 12.2.10 GENTELL
  • 12.2.11 AXIO BIOSOLUTIONS PVT. LTD.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS